Clinical Trials
4 trialsNCT03797326 2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04781088 2026-02-11
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04519151 2023-06-08
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Sheba Medical Center
Phase 2 Recruiting